BioCentury | Jun 1, 2009
Finance

Foot in door at Amylin

Activist investors appear to have gotten two hits in five tries in their proxy battle with Amylin Pharmaceuticals Inc. last week, but with only two seats on the company's 12-person board, the question is whether...
BioCentury | Feb 9, 2009
Company News

Amylin endocrine news

Eastbourne Capital Management LLC unveiled the slate of five directors it plans to nominate to Amylin's board. The diabetes company told investors on Jan. 30 that Black Bear Fund I, which is advised by Eastbourne,...
BioCentury | Feb 3, 2009
Company News

Eastbourne proposes Amylin board nominees

Eastbourne Capital Management said it plans to nominate a slate of five directors for election to the 12-member board of diabetes company Amylin (NASDAQ:AMLN). Eastbourne's proposed nominees are: M. Kathleen Behrens, an advisor to Physic...
BioCentury | Apr 10, 2000
Financial News

Exact Laboratories raises $32 million

...Ventures; Paine Webber; Robertson Stephens; Galleon Group; One Liberty Ventures; Greylock Management; Highland Capital Partners; RS Investment...
BioCentury | Feb 2, 2000
Financial News

Novavax completes private placement

...at $6.75. Lead investors included SAFECO Growth Fund; SAFECO Resource Series Trust Growth Portfolio; and RS Investment...
Items per page:
1 - 5 of 5
BioCentury | Jun 1, 2009
Finance

Foot in door at Amylin

Activist investors appear to have gotten two hits in five tries in their proxy battle with Amylin Pharmaceuticals Inc. last week, but with only two seats on the company's 12-person board, the question is whether...
BioCentury | Feb 9, 2009
Company News

Amylin endocrine news

Eastbourne Capital Management LLC unveiled the slate of five directors it plans to nominate to Amylin's board. The diabetes company told investors on Jan. 30 that Black Bear Fund I, which is advised by Eastbourne,...
BioCentury | Feb 3, 2009
Company News

Eastbourne proposes Amylin board nominees

Eastbourne Capital Management said it plans to nominate a slate of five directors for election to the 12-member board of diabetes company Amylin (NASDAQ:AMLN). Eastbourne's proposed nominees are: M. Kathleen Behrens, an advisor to Physic...
BioCentury | Apr 10, 2000
Financial News

Exact Laboratories raises $32 million

...Ventures; Paine Webber; Robertson Stephens; Galleon Group; One Liberty Ventures; Greylock Management; Highland Capital Partners; RS Investment...
BioCentury | Feb 2, 2000
Financial News

Novavax completes private placement

...at $6.75. Lead investors included SAFECO Growth Fund; SAFECO Resource Series Trust Growth Portfolio; and RS Investment...
Items per page:
1 - 5 of 5